Wayne Silverman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9584583/publications.pdf

Version: 2024-02-01

687363 713466 22 961 13 21 citations h-index g-index papers 22 22 22 1073 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Down syndrome: Cognitive phenotype. Mental Retardation and Developmental Disabilities Research Reviews, 2007, 13, 228-236.	3.6	247
2	Down syndrome and Alzheimer's disease: Common pathways, commonÂgoals. Alzheimer's and Dementia, 2015, 11, 700-709.	0.8	218
3	Dementia in Adults With Mental Retardation: Assessment at a Single Point in Time. American Journal on Intellectual and Developmental Disabilites, 2004, 109, 111.	2.4	81
4	Dementia and mild cognitive impairment in adults with intellectual disability: Issues of diagnosis. Developmental Disabilities Research Reviews, 2013, 18, 31-42.	2.9	77
5	The Alzheimer's Biomarker Consortiumâ€Down Syndrome: Rationale and methodology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12065.	2.4	49
6	Aging and Dementia among Adults with Mental Retardation and Down Syndrome. Topics in Geriatric Rehabilitation, 1998, 13, 49-64.	0.4	46
7	Stanford-Binet and WAIS IQ differences and their implications for adults with intellectual disability (aka mental retardation). Intelligence, 2010, 38, 242-248.	3.0	35
8	Alzheimerâ€Related Cerebrovascular Disease in Down Syndrome. Annals of Neurology, 2020, 88, 1165-1177.	5.3	34
9	Maladaptive Behaviors Related to Adaptive Decline in Aging Adults With Mental Retardation. American Journal on Intellectual and Developmental Disabilites, 2003, 108, 327.	2.4	29
10	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. Journal of Neurodevelopmental Disorders, 2019, 11, 20.	3.1	26
11	Promising outcome measures of early Alzheimer's dementia in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12044.	2.4	24
12	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease, 2021, 79, 671-681.	2.6	23
13	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 797.	9.0	17
14	Evaluation of the National Task Groupâ€Early Detection Screen for Dementia: Sensitivity to â€~mild cognitive impairment' in adults with Down syndrome. Journal of Applied Research in Intellectual Disabilities, 2021, 34, 905-915.	2.0	14
15	Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models. Progress in Brain Research, 2020, 251, 1-28.	1.4	13
16	The Association between Sex and Risk of Alzheimer's Disease in Adults with Down Syndrome. Journal of Clinical Medicine, 2021, 10, 2966.	2.4	8
17	Cognitive Function during the Prodromal Stage of Alzheimer's Disease in Down Syndrome: Comparing Models. Brain Sciences, 2021, 11, 1220.	2.3	6
18	Copy Number Variants Associated with 14 Cases of Self-Injurious Behavior. PLoS ONE, 2016, 11, e0149646.	2.5	5

#	Article	IF	CITATIONS
19	Probing the proteome to explore potential correlates of increased Alzheimer'sâ€related cerebrovascular disease in adults with Down syndrome. Alzheimer's and Dementia, 2022, 18, 1744-1753.	0.8	4
20	Alzheimer's risk and quality of life: History of Down syndrome as a case in point. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12171.	2.4	2
21	Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1736-1743.	0.8	2
22	Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer $\hat{a} \in \mathbb{T}^M$ s continuum. SLEEP Advances, 2022, 3, .	0.2	1